Article info

Download PDFPDF

Phase III, multicentre, randomised, double-blind, placebo-controlled, 104-week study of subcutaneous belimumab administered in combination with rituximab in adults with systemic lupus erythematosus (SLE): BLISS-BELIEVE study protocol

Authors

  1. Correspondence to Dr James Groark; james.g.groark{at}gsk.com
View Full Text

Citation

Teng YKO, Bruce IN, Diamond B, et al
Phase III, multicentre, randomised, double-blind, placebo-controlled, 104-week study of subcutaneous belimumab administered in combination with rituximab in adults with systemic lupus erythematosus (SLE): BLISS-BELIEVE study protocol

Publication history

  • Received August 14, 2018
  • Revised November 21, 2018
  • Accepted December 3, 2018
  • First published March 20, 2019.
Online issue publication 
March 20, 2019

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.